Advisory Panel Votes Against Recommending BMS, AZ Diabetes Drug

An FDA panel voted 9-6 against recommending approval of Bristol-Myers Squibb (BMS) and AstraZeneca’s diabetes drug dapagliflozin, citing cancer risks and a lack of substantial evidence.
Drug Industry Daily